Santhera Pharmaceuticals (SIX: SANN) has appointed Orlando Oliveira as chief executive officer (CEO), succeeding Dario Eklund, effective July 15, 2026.
With more than 25 years of global experience across specialty pharmaceuticals, oncology, rare diseases, and orphan drugs, Mr. Oliveira has a strong track record of building high-performing organizations, driving international expansion, and executing strategic transactions.
In a statement, Mr. Eklund, the current CEO of Santhera, commented, “After almost seven years in this role, I believe the time is right for a planned leadership transition. I have long believed that leadership renewal, at the right time, is healthy for companies—bringing fresh perspectives, renewed energy and support for the next phase of growth. Santhera today is on a solid foundation, with AGAMREE established as a growing global brand and the company in a strong and stable position for the future. Having known Orlando professionally for many years, I am confident that he is the right leader to guide Santhera in its next chapter. I will work closely with Orlando and the team to support a smooth handover and continued momentum.”
